Should accessory proteins be structural components of lentiviral vaccines?. Lessons learned from the accessory ORF-A protein of FIV

Veterinary Immunology and Immunopathology

Volumn 123, Issue 1-2, 2008, Pages 144-149

  Pistello, Mauro ^a  

^a Retrovirus Center   (Italy)

Author keywords

Cat; Feline immunodeficiency virus; FIV; Vaccine; Viral accessory proteins

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTIGEN; CD134 ANTIGEN; DNA; ORF A PROTEIN; PRIMER DNA; REGULATOR PROTEIN; STRUCTURAL PROTEIN; VIF PROTEIN; VIRUS PROTEIN; VIRUS VACCINE;

CAT; CD4+ T LYMPHOCYTE; DISEASE COURSE; EX VIVO STUDY; IMMUNE RESPONSE; IMMUNIZATION; LENTIVIRINAE; NONHUMAN; PROTEIN STRUCTURE; SHORT SURVEY; VIREMIA; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; CATS; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; IMMUNODEFICIENCY VIRUS, FELINE; VIRAL PROTEINS; VIRAL VACCINES;

ANIMALIA; FELINE IMMUNODEFICIENCY VIRUS; LENTIVIRUS;

EID: 43049168969     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetimm.2008.01.020     Document Type: Short Survey

References (36)

1. Allen T.M., Altfeld M., Geer S.C., Kalife E.T., Moore C., O'sullivan K.M., Desouza I., Feeney M.E., Eldridge R.L., Maier E.L., Kaufmann D.E., Lahaie M.P., Reyor L., Tanzi G., Johnston M.N., Brander C., Draenert R., Rockstroh J.K., Jessen H., Rosenberg E.S., Mallal S.A., and Walker B.D. Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J. Virol. 79 (2005) 13239-13249
2. Bour S., and Strebel K. The HIV-1 Vpu protein: a multifunctional enhancer of viral particle release. Microbes Infect. 5 (2003) 1029-1039
3. Brander C., Frahm N., and Walker B.D. The challenges of host and viral diversity in HIV vaccine design. Curr. Opin. Immunol. 18 (2006) 430-437
4. Chatterji U., de Parseval A., and Elder J.H. Feline immunodeficiency virus OrfA is distinct from other lentivirus transactivators. J. Virol. 76 (2002) 9624-9634
5. Croft M. Costimulation of T cells by OX40, 4-1BB, and CD27. Cytokine Growth Factor Rev. 14 (2003) 265-273
6. Dean G.A., LaVoy A., and Burkhard M.J. Peptide mapping of feline immunodeficiency virus by IFN-gamma ELISPOT. Vet. Immunol. Immunopathol. 100 (2004) 49-59
7. Duerr A., Wasserheit J.N., and Corey L. HIV vaccines: new frontiers in vaccine development. Clin. Infect. Dis. 43 (2006) 500-511
8. Emerman M., and Malim M.H. HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. Science 280 (1998) 1880-1884
9. Ensoli B., Fiorelli V., Ensoli F., Cafaro A., Titti F., Butto S., Monini P., Magnani M., Caputo A., and Garaci E. Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. AIDS 20 (2006) 2245-2261
10. Gebhard D.H., Dow J.L., Childers T.A., Alvelo J.I., Tompkins M.B., and Tompkins W.A. Progressive expansion of an L-selectin-negative CD8 cell with anti-feline immunodeficiency virus (FIV) suppressor function in the circulation of FIV-infected cats. J. Infect. Dis. 180 (1999) 1503-1513
11. Gemeniano M.C., Sawai E.T., Leutenegger C.M., and Sparger E.E. Feline immunodeficiency virus ORF-A is required for virus particle formation and virus infectivity. J. Virol. 77 (2003) 8819-8830
12. Gemeniano M.C., Sawai E.T., and Sparger E.E. Feline immunodeficiency virus ORF-A localizes to the nucleus and induces cell cycle arrest. Virology 325 (2004) 167-174
13. Geyer M., Fackler O.T., and Peterlin B.M. Structure-function relationships in HIV-1 Nef. EMBO Rep. 2 (2001) 580-585
14. Girard M.P., Osmanov S.K., and Kieny M.P. A review of vaccine research and development: the human immunodeficiency virus (HIV). Vaccine 24 (2006) 4062-4081
15. Goulder P.J., and Watkins D.I. HIV and SIV CTL escape: implications for vaccine design. Nat. Rev. Immunol. 4 (2004) 630-640
16. Gruters R.A., van Baalen C.A., and Osterhaus A.D. The advantage of early recognition of HIV-infected cells by cytotoxic T-lymphocytes. Vaccine 20 (2002) 2011-2015
17. Gupta S., Leutenegger C.M., Dean G.A., Steckbeck J.D., Cole K.S., and Sparger E.E. Vaccination with attenuated feline immunodeficiency virus proviral DNA vaccine expressing interferon gamma. J. Virol. 81 (2007) 465-473
18. Huisman W., Schrauwen E., Pas S., van Amerongen G., Tijhaar E., and Osterhaus A.D. FIV vaccination with recombinant vector vaccines expressing Rev and ORF-A. 7th International Feline Retrovirus Research Symposium. Pisa, September 2004 (2004) 77
19. Inoshima Y., Miyazawa T., and Mikami T. The roles of vif and ORF-A genes and AP-1 binding site in in vivo replication of feline immunodeficiency virus. Arch. Virol. 143 (1998) 789-795
20. Le Rouzic E., and Benichou S. The Vpr protein from HIV-1: distinct roles along the viral life cycle. Retrovirology 22 (2005) 11
21. Lockridge K.M., Chien M., Dean G.A., Stefano Cole K., Montelaro R.C., Luciw P.A., and Sparger E.E. Protective immunity against feline immunodeficiency virus induced by inoculation with vif-deleted proviral DNA. Virology 273 (2000) 67-79
22. Lockridge K.M., Himathongkham S., Sawai E.T., Chienand M., and Sparger E.E. The feline immunodeficiency virus vif gene is required for productive infection of feline peripheral blood mononuclear cells and monocyte-derived macrophages. Virology 261 (1999) 25-30
23. McMichael A.J. HIV vaccines. Annu. Rev. Immunol. 24 (2006) 227-255
24. Navarro F., and Landau N.R. Recent insights into HIV-1 Vif. Curr. Opin. Immunol. 16 (2004) 477-482
25. Paul T.A., Casey J.W., Avery R.J., and Sutton C.A. Expression of feline immunodeficiency virus Vif is associated with reduced viral mutation rates without restoration of replication of vif mutant viruses. Virology 361 (2007) 112-122
26. Phillips T.R., Lamont C., Konings D.A., Shacklett B.L., Hamson C.A., Luciw P.A., and Elder J.H. Identification of the Rev transactivation and Rev-responsive elements of feline immunodeficiency virus. J. Virol. 66 (1992) 5464-5471
27. Pistello M., Bonci F., Flynn J.N., Mazzetti P., Isola P., Zabogli E., Camerini V., Matteucci D., Freer G., Pelosi P., and Bendinelli M. AIDS vaccination studies with an ex vivo feline immunodeficiency virus model: analysis of the accessory ORF-A protein and DNA as protective immunogens. J. Virol. 80 (2006) 8856-8868
28. Pistello M., Bonci F., Isola P., Mazzetti P., Merico A., Zaccaro L., Matteucci D., and Bendinelli M. Evaluation of feline immunodeficiency virus ORF-A mutants as candidate attenuated vaccine. Virology 332 (2005) 676-690
29. Pistello M., Moscardini M., Mazzetti P., Macchi S., Bonci F., Isola P., Freer G., Matteucci D., Specter S., and Bendinelli M. Development of feline immunodeficiency virus ORF-A (tat) mutants: in vitro and in vivo characterization. Virology 298 (2002) 84-95
30. Shimojima M., Miyazawa T., Ikeda Y., McMonagle E.L., Haining H., Akashi H., Takeuchi Y., Hosie M.J., and Willett B.J. Use of CD134 as a primary receptor by the feline immunodeficiency virus. Science 303 (2004) 1192-1195
31. Sirriyah J., Dean G.A., LaVoy A., and Burkhard M.J. Assessment of CD4+ and CD8+ IFN-gamma producing cells by ELISPOT in naive and FIV-infected cats. Vet. Immunol. Immunopathol. 102 (2004) 77-84
32. Sparger E.E. FIV as a model for HIV: an overview. In: Friedman H., Bendinelli M., and Specter S. (Eds). Animal Models of HIV Infection and Control (2006), Springer, New York, NY 149-237
33. Steffens C.M., and Hope T.J. Recent advances in the understanding of HIV accessory protein function. AIDS 15 Suppl. 5 (2001) S21-S26
34. Tomonaga K., Norimine J., Shin Y.S., Fukasawa M., Miyazawa T., Adachi A., Toyosaki T., Kawaguchi Y., Kai C., and Mikami T. Identification of a feline immunodeficiency virus gene which is essential for cell-free virus infectivity. J. Virol. 66 (1992) 6181-6185
35. Tomonaga K., Shin Y.S., Fukasawa M., Miyazawa T., Adachi A., and Mikami T. Feline immunodeficiency virus gene expression: analysis of the RNA splicing pattern and the monocistronic rev mRNA. J. Gen. Virol. 74 (1993) 2409-2417
36. Yu X.G., Lichterfeld M., Addo M.M., and Altfeld M. Regulatory and accessory HIV-1 proteins: potential targets for HIV-1 vaccines?. Curr. Med. Chem. 12 (2005) 741-747